While many are in early phase studies, most of the new topical options are targeting sebum reduction, a novel pathway to controlling acne, and the data are exciting, one expert says.
Allergan announced in late February that the FDA approved its topical Aczone (dapsone) Gel, 7.5% for treatment of acne vulgaris.
Misconceptions about hidradenitis suppurativa (HS) prevent dermatologists and other clinicians from properly diagnosing and treating what one expert says is a “crippling disease.”
Research shows dermatologists are overprescribing antibiotics for acne treatment, and patients and their parents seem unaware of the consequences, as well as alternatives to antibiotic treatment for acne.
A novel cell-based strategy tested in mice can detect the onset of psoriasis flares by measuring disease biomarkers and then release therapeutic proteins to stop progression. Future implications are exciting.
As research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.
Study demonstrates current antibiotic use for acne therapy far surpasses guideline recommendations and calls for dermatologists to decrease extended courses of antibiotics through early recognition of failure and guiding patients to alternative therapies.
Researchers have uncovered new information about the pathogenetic similarities and differences between cutaneous psoriasis and psoriatic arthritis in a recent study. They hope the information, one day, leads to a test to help doctors determine which psoriasis patients will advance with psoriatic disease.
New research indicates that treatment results for patients with mild-to-moderate acne might be better with combinations of light colors with photodynamic therapy (PDT).
Topical 90 percent medical grade kanuka honey and 10 percent glycerin may be an effective rosacea treatment, according to a study.